top of page
Suche

Clin Cancer Res. 2022 Nov

  • christineeulenburg
  • 1. Jan. 2023
  • 1 Min. Lesezeit

Impact of RNA signatures on pCR and survival after 12-week neoadjuvant pertuzumab plus trastuzumab with or without paclitaxel in the WSG-ADAPT-HER2+/HR- trial. Monika Graeser et al.

CCR-22-1587.

doi: 10.1158/1078-0432.CCR-22-1587.

 
 
 

Aktuelle Beiträge

Alle ansehen
JAMA. 2023 Oct

Adherence to CPAP Treatment and the Risk of Recurrent Cardiovascular Events: A Meta-Analysis. Sánchez-de-la-Torre M, Gracia-Lavedan E,...

 
 
 
JAMA Oncol. 2023 Jul

Efficacy of Endocrine Therapy Plus Trastuzumab and Pertuzumab vs De-escalated Chemotherapy in Patients with Hormone...

 
 
 
J Clin Oncol. 2023 Aug

De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+...

 
 
 

Comments

bottom of page